The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
Japan’s Eisai and US biotech Biogen today revealed that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved Leqembi (lecanemab) for the treatment of Alzheimer’s disease (AD). 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
Vertex Pharmaceuticals has reported product revenues of $2.3 billion in the third quarter of 2022, an 18% increase on the same period of last year, while upping its revenue guidance for the year to around $8.85 billion. 28 October 2022
Chief executive Paul Hudson presented an upbeat results statement for Sanofi Friday morning, highlighting strong performance in the third quarter and a range of clinical developments under way. 28 October 2022
The pharmaceutical industry in Europe has questioned measures aimed at improving the way wastewater is treated by countries within the European Union. 28 October 2022
Gilead Sciences announced its financial results for the third quarter of 2022 after markets closed yesterday, but the US biotech major’s shares were up 4.8% at $73.58 pre-market today. 28 October 2022
Markets seemed unfazed, as GSK’s (LSE: AZN) shares barely moved on the news yesterday that it was discontinuing a development program for otilimab, as a result of mediocre performance of the drug in rheumatoid arthritis. 28 October 2022
The European Medicines Agency (EMA) has accepted the filing of the Marketing Authorization Application (MAA) for lebrikizumab for the treatment of moderate to severe atopic dermatitis submitted by Almirall. 28 October 2022
Shares in Merck & Co were nearly 2% higher at lunchtime Thursday after the US pharma giant presented its third quarter 2022 financial results. 27 October 2022
US immuno-oncology cell therapy company 2seventy bio’s shares gained 3.5% to $16.00 this morning, as it announced a strategic alliance with Chinese biotech JW Therapeutics. 27 October 2022
Positive top-line results from two global Phase III studies, BALATON and COMINO, evaluating the first and only bispecific antibody for the eye, Vabysmo (faricimab), in macular edema due to branch and central retinal vein occlusion (BRVO and CRVO) were released today by Swiss pharma giant Roche. 27 October 2022
Japan’s largest drugmaker Takeda Pharmaceutical’s shares edged 1.8% higher to $12.97 in early US trading, after it reported financial results for the first half of its fiscal year ended September 2022. 27 October 2022
Anglo-Swedish pharma major AstraZeneca has presented new results on Ultomiris (ravulizumab) in neuromyelitis optica spectrum disorder (NMOSD). 27 October 2022
A fairly positive outcome from a meeting of the US regulator’s scientific panel raises the prospect that pharma major GSK may be able to succeed where its British counterpart AstraZeneca has failed. 27 October 2022
Rare diseases specialist Swedish Orphan Biovitrum saw its shares fall more than 3% to 204.40 kronor this morning after releasing third-quarter 2022 financial result. 27 October 2022
The US Food and Drug Administration (FDA) yesterday released its fiscal year (FY) 2023 Generic Drug User Fee Amendments (GDUFA) Science and Research Priority Initiatives. 27 October 2022
In the USA, the Biden-Harris Administration has made expanding access to health insurance and lowering health care costs for America’s families a top priority, and, starting now, consumers can preview their health care coverage options and see the savings available to them in the most competitive Marketplace in history. 27 October 2022
The questions that were posed to the biopharmaceutical industry in 2020 were more urgent than ever before, as the COVID-19 pandemic brought much of the world to a standstill. 27 October 2022
A US regulatory submission from microbiome company Seres Therapeutics has been accepted, with an expected decision date of April 26, 2023. 26 October 2022
Australia’s largest biotech CSL Limited today revealed it has entered into a strategic option and license agreement with Arizona, USA-based Translational Sciences for rights to its enhanced thrombus (blood clot) dissolving drug candidate, TS23. 26 October 2022